Testing camonsertib with radiation therapy for returning head and neck cancer
Tests camonsertib plus precise radiation in adults with head and neck cancer that returned.
Key facts
- Who runs it
- National Cancer Institute (NCI)
- Where
- Duarte, Irvine, Lexington, and Pittsburgh, United StatesSee the 4 sites
- Trial code
- Registry title
- Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 39 people, planned
- Starts
- 13 Feb 2027
- Expected to end
- 31 May 2029
- Type of study
- Interventional
- Treatments tested
- Biospecimen Collection
- Camonsertib
- Computed Tomography
- Positron Emission Tomography
- Stereotactic Body Radiation Therapy
- Record updated
- 29 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose head and neck squamous cell cancer has come back in an area already treated with radiation and cannot be removed by surgery. It tests camonsertib together with stereotactic body radiation therapy.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Recurrent head and neck squamous cell cancer (mouth, throat, voice box, lower throat or sinus, or neck lymph nodes with unknown primary) that cannot be removed by surgery. It must be growing in a previously irradiated area and be measurable on scans.
- Earlier treatment
- Earlier radiation to the head and neck must have been at least 30 Gy and no more than 80 Gy, and must have ended at least 6 months before joining. There are no requirements about earlier drug treatments.
Main reasons for not taking part
- Cancer that has spread to distant parts of the body
- More than one earlier course of head and neck radiation over the area to be treated
- Cancer surrounding more than 180 degrees of the carotid artery, or tumors growing into the jaw bone or through the skin
- Pregnant women
- Scleroderma, or taking certain strong interacting drugs (CYP3A4/5, P-gp or BCRP)
The registry criteria, word for word
Show all 33 criteriaShow less
Who can take part
- Patients must have histologically confirmed recurrent or metachronous (second primary) unresectable head and neck squamous cell carcinoma involving the oral cavity, oropharynx, larynx, hypopharynx, and/or paranasal sinus, or cervical lymphadenopathy with unknown primary. Core needle biopsy (preferably at least three 18-gauge cores) or incisional biopsy is preferred over fine needle aspiration (FNA) for diagnosis of recurrent disease or new primary head and neck squamous cell carcinoma to provide sufficient tumor tissue for correlative studies. Unresectable refers both to patients who have declined surgery and patients deemed unresectable by otolaryngology. This includes patients for whom curative resection is medically contraindicated and/or would be associated with excessive surgical risk (as deemed by the consulting otolaryngologist) or undue surgical morbidity (e.g., total glossectomy, laryngectomy, and/or major resection requiring free flap reconstruction). There are no requirements related to prior systemic therapies that patients may have received
- Patients must have recurrent disease within a previously irradiated area (radiotherapy to dose ≥ 30 gray [Gy] and ≤ 80 Gy; in-field recurrence)
- Patients must have completed prior radiotherapy at least 6 months prior to enrollment. Due to safety concerns, reirradiation within less than 6 months to the head and neck is very rarely recommended per standard of care
- Patients must have measurable disease (at least one measurable lesion) as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Baseline imaging must include neck CT (preferably contrast-enhanced) and chest CT or skullbase to midthigh PET/CT (preferably with contrast-enhanced neck CT if diagnostic contrast-enhanced neck CT not available). Patients who have undergone surgery aside from biopsy may be included if gross disease is present within the surgical resection bed or at another site
- Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of camonsertib in combination with radiotherapy in patients < 18 years of age, children are excluded from this study
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%)
- Leukocyte count ≥ 3,000/mcL
- Absolute neutrophil count ≥ 1,500/mcL
- Platelets ≥ 100,000/mcL
- Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L without transfusion or erythropoietin dependency (within 7 days of assessment)
- Serum bilirubin ≤ 1.5 × institutional upper limit of normal (ULN) (if total serum bilirubin > 1.5 × institutional ULN, then direct bilirubin must be < ULN)
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 3 × institutional ULN
- Albumin > 2.5 mg/dL
- Glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m\^2; GFR can be measured directly or estimated using the site's institutional standards
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better
- Ability to take pills by mouth
- The effects of camonsertib on the developing human fetus are unknown. For this reason and because ATR inhibitors and radiation are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after completion of camonsertib administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
- Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants
Who cannot take part
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1), with the exception of alopecia
- Patients who are receiving any other investigational agents for a current cancer diagnosis
- Patients who have received more than one prior course of head and neck radiotherapy overlapping the region to be treated with the current diagnosis of head and neck cancer
- Pregnant women are excluded from this study because camonsertib is an ATR inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with camonsertib, breastfeeding should be discontinued if the mother is treated with camonsertib. These potential risks may also apply to other agents used in this study
- Concomitant use of strong CYP3A4/5 inhibitors and inducers, and strong P-gp and BCRP inhibitors; Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
- Patients with distant metastatic disease
- Patients who have disease surrounding > 180 degrees of the carotid artery
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to camonsertib or radiation
- Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous
- Patients with tumors invading the mandible or tumors with gross skin involvement (i.e., tumor ulceration through the skin)
- Patients diagnosed with scleroderma
Where in United States
- City of Hope Comprehensive Cancer CenterDuarte, United StatesContact: Sean Maroongroge (principal investigator)Taking people
- City of Hope at Irvine LennarIrvine, United StatesContact: Sean Maroongroge (principal investigator)Taking people
- University of Kentucky/Markey Cancer CenterLexington, United StatesContact: Susanne M. Arnold (principal investigator)Taking people
- UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Yvonne M. Mowery (principal investigator)Taking people
About the trial
What the trial wants to find out
This phase I trial tests the safety, side effects, and best dose of camonsertib in combination with stereotactic body radiation therapy in controlling disease in patients with head and neck squamous cell cancer that has come back after a period of improvement (recurrent) or that cannot be removed by surgery (unresectable). Camonsertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Giving camonsertib in combination with stereotactic body radiation therapy may help control disease in patients with recurrent or unresectable head and neck squamous cell cancers.
The group in the trial
- Treatment (camonsertib, SBRT)Treatment being tested
Patients undergo 4 or 5 treatment fractions of SBRT twice weekly, 2-3 days apart between fractions, over 3 weeks. Patients receive camonsertib PO QD on the day of and the day after each radiation therapy treatment. Patients also undergo PET/CT or CT and collection of blood samples throughout the trial.
Treatment: Biospecimen Collection, Camonsertib, Computed Tomography, Positron Emission Tomography, and Stereotactic Body Radiation Therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Phase I Trial of ATR Inhibitor Camonsertib Combined With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
- Plain-language title
- Testing camonsertib with radiation therapy for returning head and neck cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 29 October 2026